Biotech News

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Virios Therapeutics (VIRI)Virios Therapeutics2026-04-23 13:00 ESTPartnership

VIRI (VIRI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is viri.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VIRIVirios Therapeutics2026-01-12 13:30 EST

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

OGENOragenics2025-10-07 12:30 EST

Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

VIRIVirios Therapeutics2026-04-15 13:00 EST

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

SCYXSCYNEXIS2025-11-17 15:15 EST

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections

OGENOragenics2026-05-07 12:30 EST

Oragenics Signs Letter of Intent to License CardioDialysis™ Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation

ANTXAN2 Therapeutics2025-11-10 12:00 EST

AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)

ABUSArbutus2025-06-25 11:30 EST

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

ASMBAssembly Biosciences2025-12-22 13:00 EST

Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

SPROSpero Therapeutics2024-10-16 16:05 EST

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

View all latest news

Virios Therapeutics

Virios Therapeutics is a biotechnology company focused on viral-trigger and inflammation biology, with an emphasis on chronic disease programs. Its story is built around a narrow disease hypothesis and early-stage development.

Recent company news

VIRIVirios Therapeutics2026-07-20 12:30 EST

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

VIRIVirios Therapeutics2026-05-18 12:45 EST

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-05-07 12:30 EST

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biopharma
Location: United States